Clin2
NCT07086391Possibly a fitRecruiting

Inhaled Polymyxin B for Resistant Pneumonia

Carbapenem-Resistant Enterobacteriaceae InfectionPneumonia - Bacterial

Part of Infections, Lungs & breathing clinical trials.

This trial tests different ways of giving an inhaled antibiotic (polymyxin B) to people on a ventilator who have pneumonia caused by tough bacteria that don't respond to usual antibiotics. The goal is to find the best way to deliver the medicine to help clear the infection.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
144 people
Ages
18 years to 90 years
Study type
Observational

Who can take part

  • You have pneumonia confirmed by chest X-ray and symptoms like fever or cough.
  • A lab test shows the bacteria causing your pneumonia is resistant to common strong antibiotics but can be treated with polymyxin B.
  • You are on a breathing machine (ventilator) with a tube in your airway.
  • You will receive the inhaled polymyxin B treatment for at least 3 days.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06602557Recruiting· Phase 2
Inhaled antibiotic for lung infection during ECMO support

This trial tests whether adding an inhaled antibiotic (amikacin) to standard IV antibiotics can better treat a serious lung infection (pneumonia caused by Gram-negative bacteria) in patients on a heart-lung machine (ECMO) and a breathing tube. If you or your loved one is on ECMO and has this type of pneumonia, this study may offer a new treatment approach.

Paris
NCT07124468Recruiting· Phase 1
Antibiotic levels in lungs of healthy adults

This trial tests how a new antibiotic (meropenem-pralubactam) moves into the lungs of healthy people in China. You will receive the medicine through an IV, and a lung fluid sample will be collected to measure the drug levels.

Fuzhou
NCT07512596Not yet recruiting· Phase 2
Study of a new antibiotic for hospital pneumonia from resistant bacteria

This trial tests a drug called Polymyxin E2 Methanesulfonate for a serious lung infection that patients can get in the hospital, caused by bacteria that don't respond to common antibiotics. It may be an option for people on ventilators or recently hospitalized with pneumonia that standard drugs can't treat.

Bengbu, Anhui
NCT06819462Not yet recruiting
Inhaled antibiotic to prevent pneumonia in brain injury patients

This trial tests whether breathing in an antibiotic called polymyxin E can prevent pneumonia in people with brain injury who are on a breathing machine. It may help reduce lung infections in the ICU.

NCT06907069Enrolling by invitation· Phase 4
Combined treatment for drug-resistant bacteria in lung infections

This trial tests if giving a medication (colistin) both through an IV and as a mist you breathe in works better for lung infections caused by bacteria that are hard to treat with standard antibiotics. It may help patients who have these tough bacteria and are in the hospital.

Ningbo, Z
NCT07759934Recruiting· Phase 2
Comparing ASK0912 to polymyxin B for hospital-acquired pneumonia

This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.

Nanjing, Jiangsu

Hear when a new Carbapenem-Resistant Enterobacteriaceae Infection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.